RxDoctor Payments Data

Vivienne Gomes, MD

Psychiatry · Washington, DCNPI 1134430655

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 220 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 36.7% of the total. Reporting peaked in 2021 at $1,856 and has fallen 89.3% since, to $199 in 2025. Among psychiatry clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,889in general payments, 2019–2025

Across 220 payments — averaging $26.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$2K
  • AbbVie$1K
  • Otsuka America Pharmaceutical, Inc.$949
  • Alkermes, Inc.$711
  • Neurocrine Biosciences, Inc.$210
  • Johnson & Johnson$167
  • plus $263 from 5 others

What the payments were for

  • Food & beverage$5,85999%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,889 in reported general payments places this provider in the 95th percentile of 226 psychiatry providers in District of Columbia.

See all psychiatry providers in District of Columbia

Medicare billing

Part B allowed, 2024
$9,697
Medicare patients
39
Services billed
101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clozapine82$3,440
Vilazodone Hcl26$2,118
Duloxetine Hcl39$951
Mirtazapine60$855
Benztropine Mesylate41$468
Lurasidone Hcl23$413
Clonazepam30$377
Hydroxyzine Pamoate25$358
Prazosin Hcl15$295
Haloperidol14$287
Fluoxetine Hcl41$285
Lamotrigine21$277
Sertraline Hcl27$267
Quetiapine Fumarate19$260
Risperidone13$230

Paid to pharmacies, not to this prescriber.

Other psychiatry in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →